You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page
Type 2 Inflammation
What treatments may be needed to achieve remission? And In what percentage of patients could remission be a target?
Prof. Hellings and Prof. Corso highlight that disease severity plays a key role in rate and control of remission in CRS.
Learning objectives
Understand the importance of considering patient heterogeneity in Chronic Rhinosinusitis (CRS) treatment, including the differentiation between mild, moderate, and severe cases, and the implications for achieving control and remission
Recognize the significance of long-term observation and sustained control in evaluating the effectiveness of treatments, particularly the role of biologics in severe cases, and the necessity of continuous monitoring to confirm sustained remission
Understand the role of type of the patients, severity of the disease, the endotype, and treatments that are evaluated in determining the percentage of patients to target for remission
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.